GlaxoSmithKline (Opiates Business Australia)

GlaxoSmithKline (Opiates Business Australia) Overview

Status Acquired/​Merged
Employees 185
Employees
Latest Deal Type Buyout/​LBO
Financing Rounds 1

GlaxoSmithKline (Opiates Business Australia) General Information

Description

Operator of opiates business in Australia. The company extracts and manufactures narcotic opioid alkaloids found as natural products in the opium poppy plant which are used to produce analgesics for the treatment of moderate to severe pain.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Specialty Chemicals
Acquirer
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

GlaxoSmithKline (Opiates Business Australia) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GlaxoSmithKline (Opiates Business Australia)‘s full profile, request access.

Request a free trial

GlaxoSmithKline (Opiates Business Australia) Executive Team (1)

Name Title Board Seat Contact Info
Steve Morris General Manager

GlaxoSmithKline (Opiates Business Australia) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GlaxoSmithKline (Opiates Business Australia)‘s full profile, request access.

Request a free trial